A newly published study suggests that cannabidiol may work alongside methotrexate — the most commonly prescribed drug for rheumatoid arthritis — to reduce joint inflammation more effectively than the medication alone.
The research, published April 8 in the journal International Immunopharmacology by a team led by Cheng Xiao, found that combining CBD with methotrexate produced dose-dependent effects that significantly reduced joint swelling, inflammation, and bone erosion in preclinical models of arthritis. A medium dose of the combination reportedly achieved results comparable to high-dose methotrexate on its own, according to the study authors.
The findings are notable in part because methotrexate, while effective, carries well-documented side effects including liver toxicity and reproductive harm. The researchers reported that CBD appeared to protect against methotrexate-induced testicular toxicity and reproductive damage — a finding that could have implications for how the drug is prescribed if confirmed in human trials.
At the molecular level, the team identified a specific mechanism: CBD appeared to suppress inflammatory macrophage activation by inhibiting the STAT3 and NF-κB signaling pathways, which play a central role in driving the chronic inflammation characteristic of rheumatoid arthritis.
“The combination strategy offers enhanced anti-inflammatory benefits while reducing the toxic side effects associated with traditional methotrexate treatment,” the authors wrote.
The study adds to a growing body of preclinical research exploring how cannabinoids may complement existing pharmaceutical treatments. However, the results have not yet been replicated in human clinical trials, and researchers cautioned that further investigation is needed before any clinical recommendations can be made.
Rheumatoid arthritis affects an estimated 1.3 million Americans, according to the Arthritis Foundation.
For consumers interested in learning more about CBD products and their reported uses, [FindMyCBD.com](https://findmycbd.com) maintains a directory of options organized by category.
—
Sources: International Immunopharmacology (Xu et al., April 8, 2026); PubMed PMID 41955700
